Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Rhea-AI Summary

Bio-Path Holdings (OTCQB: BPTH), a clinical-stage biotech company, received updated coverage from Stonegate Capital Partners for Q1 2025. The company specializes in RNA interference therapeutics using its DNAbilize platform technology, which delivers antisense oligonucleotides with neutral charge and reduced toxicity. Their lead drug candidate prexigebersen (BP1001) targets Grb2 protein and is in Phase 2 trials for acute myeloid leukemia (AML). The company's pipeline includes BP1001-A in Phase 1/1b for solid tumors, BP1002 targeting Bcl-2 for blood cancers and solid tumors, and BP1003, a STAT3 inhibitor for pancreatic cancer awaiting IND application. Phase 2 data for prexigebersen shows promising potential for FDA approval in AML treatment.

Positive

• Phase 2 prexigebersen data indicates potential for FDA approval in AML treatment
• BP1001-A showing early efficacy signs in advanced solid tumors
• Diversified pipeline with multiple drug candidates in development
• Robust patent portfolio protecting proprietary technology

Negative

• Company trades on OTCQB market rather than major exchange
• Early clinical stage company with no approved products yet
• Multiple ongoing trials require significant capital expenditure

News Market Reaction

-6.50%

1 alert

-6.50% News Effect

On the day this news was published, BPTH declined 6.50%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company's lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Phase 2 prexigebersen data shows potential for FDA approval in AML treatment.
• BP1001-A trial shows early signs of efficacy in advanced solid tumors.
• Advancing pipeline backed by strategic R&D and a robust patent portfolio.

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.

Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254522

FAQ

What is Bio-Path Holdings' (BPTH) main drug candidate and its current development stage?

Bio-Path's lead drug candidate is prexigebersen (BP1001), which targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML).

What is Bio-Path Holdings' (BPTH) proprietary technology platform?

Bio-Path utilizes the DNAbilize platform technology, which delivers neutral-charge, liposomal antisense oligonucleotides with enhanced drug stability and cellular uptake while minimizing toxicity.

What are the key drug candidates in Bio-Path Holdings' (BPTH) pipeline?

The pipeline includes prexigebersen (BP1001) for AML, BP1001-A for solid tumors, BP1002 targeting Bcl-2 for blood cancers and solid tumors, and BP1003 for pancreatic cancer.

What were the main updates in Stonegate Capital Partners' Q1 2025 coverage of BPTH?

The coverage highlighted Phase 2 prexigebersen data showing potential for FDA approval in AML treatment, BP1001-A's early efficacy in advanced solid tumors, and the company's advancing pipeline supported by strategic R&D and patent portfolio.

What additional indications is Bio-Path Holdings (BPTH) exploring with BP1001-A?

BP1001-A has shown promise in preclinical studies for obesity and type 2 diabetes, in addition to its current Phase 1/1b trials for solid tumors.